Trial Profile
Improving the Efficacy of Anti-Nicotine Immunotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs NIC 002 (Primary)
- Indications Drug dependence
- Focus Therapeutic Use
- Acronyms PETNic002
- 07 Nov 2014 New trial record